quinta-feira, 5 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 31, 2025

Chevron Reports Third Quarter 2025 Results

View original at finance.yahoo.com
Chevron Reports Third Quarter 2025 Results Reported earnings of $3.5 billion; adjusted earnings of $3.6 billion Record production of 4.1 million BOE per day; 21 percent higher than last year Cash flow from operations of $9.4 billion; adjusted free cash flow of $7.0 billion HOUSTON, October 31, 2025--(BUSINESS WIRE)--Ch…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • U.S. and worldwide production hit new company records, up 27 percent and 21 percent, respectively, from last year

    80% confidence

  • The integration of Hess is progressing well, unlocking synergies across our operations and positioning Chevron as a premier global energy company

    80% confidence

  • The company returned $6 billion of cash to shareholders in the quarter, and over $78 billion in the last 3 years

    80% confidence

  • Third quarter results reflect record production, strong cash generation and sustained superior cash returns to shareholders

    80% confidence

  • Strong cash flow from operations was sustained while the company's adjusted free cash flow increased more than 50 percent from a year ago

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,549 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Chevron Reports Third Quarter 2025 Results — Source | Via News | pt.VIA.NEWS